Plain-English translation of NCT06021197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing an NMDA-enhancer to see if it can help improve thinking and memory problems in people with schizophrenia. Many people with schizophrenia find that even when their main symptoms (like hallucinations or delusions) get better with treatment, they still struggle with concentration, memory, and learning. This study wants to know if the medication can help with those thinking problems.
Even when schizophrenia symptoms improve with current treatments, many patients continue to have trouble with memory, focus, and thinking skills. Researchers believe this medication may help by working on a specific brain system involved in these cognitive problems, offering hope for better overall quality of life and functioning.
You likely qualify if…
You likely don't qualify if…
You would stay on your current schizophrenia medication and come to the clinic for a 12-week study. You would be randomly assigned to receive either the new medication or a placebo (a pill with no active ingredient), and neither you nor the researchers would know which you're getting. You would have visits at the start and end of the study, plus checkups at weeks 4 and 8, where doctors would test your thinking, memory, mood, and quality of life, and watch for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Taiwan